Journal de Fertilization: In Vitro - IVF-Worldwide, Médecine de la Reproduction, Génétique & Biologie des Cellules Souches
Libre accès
ISSN: 2375-4508
ISSN: 2375-4508
Paul R Brezina
Traditionally, ovulation induction (OI) with intrauterine insemination (IUI) has been a strategy used to maximize pregnancy outcomes in patients attempting pregnancy. A common pattern of performing OI/IUI historically has been to begin OI using oral medications, such as Clomiphene Citrate or Letrozole, and then escalating medical management to include injectable Gonadotropins such as follicle stimulating hormone (FSH). However, current medical literature shows Gonadotropin IUI to be associated inferior to other available fertility therapies in terms of both medical risks and cost-effectiveness. Therefore, Gonadotropin IUI is now thought to be a suboptimal intervention for many patients. Based on current medical literature, the role of Gonadotropin IUI is likely to continually decline in the future. This trend will benefit patients by decreasing medical risks and increasing the cost-effectiveness of fertility treatments.